Having worked in the field of tumor immunology and on the development of the first tumor vaccine to be approved by a regulatory body (Melacine), I am fascinated by novel approaches to cancer immunotherapy.
We hope to utilize this crowdfunding campaign as a stepping stone toward larger future campaigns. Batu hopes to not only progress the science behind its anti-angiogenic cancer vaccine, VallovaxTM, but to also capitalize on the non-dilutive investment and support from the surrounding community.
We are raising funds to get FDA approval for our new lung cancer vaccine ValloVax. Animal data is promising and the vaccine appears to have no side effects.
In this video, Samuel Wagner, President and CEO of Batu Biologics, discusses the significance of the tumor endothelium as the first immunological barrier masking the tumor from detection and destruction by the host’s immune system.
Currently the strongest evidence points to Govallo’s Vaccine, termed VG-1000, as working through inhibiting production of new blood vessels in tumors. We are aggressively pursuing this hypothesis as an underlying theme in our developmental experiments.